FMI
NKTR icon

F/M Investments’s Nektar Therapeutics NKTR Stock Holding History

F/M Investments’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.4M Buy
61,104
+2,981
+5% +$170K 0.29% 73
2025
Q4 		$2.46M Buy
58,123
+5,035
+9% +$282K 0.09% 212
2025
Q3 		$3.02M Buy
+53,088
New +$1.76M 0.12% 185

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

F/M Investments's NKTR Position: Q1 2026 in Review

F/M Investments increased its Nektar Therapeutics (NKTR) stake by 5.1% in Q1 2026, buying an estimated $170K and bringing the position to 61,104 shares worth $4.4M. The position accounts for 0.29% of the portfolio, ranked #73.

F/M Investments first reported a position in NKTR in Q3 2025 and has held it in 3 quarters since. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • F/M Investments held 61,104 shares of Nektar Therapeutics worth $4.4M as of Q1 2026.
  • F/M Investments bought 2,981 Nektar Therapeutics shares in Q1 2026, an estimated $170K.
  • Nektar Therapeutics made up 0.29% of F/M Investments's portfolio in Q1 2026, its #73 holding.
  • F/M Investments first reported a position in Nektar Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on F/M Investments's 13F filing for Q1 2026, filed 11 May 2026.